| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/08/2001 | WO2001015752A1 Phospholipid-coated implants |
| 03/08/2001 | WO2001015749A1 Biocompatible polymeric material |
| 03/08/2001 | WO2001015745A1 Method and formula for tumor remission and suppression of cancer |
| 03/08/2001 | WO2001015744A1 Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| 03/08/2001 | WO2001015737A2 Method for coupling molecules |
| 03/08/2001 | WO2001015732A1 Remedies for immunological diseases |
| 03/08/2001 | WO2001015730A1 DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/08/2001 | WO2001015726A2 Compositions for stimulating cytokine secretion and inducing an immune response |
| 03/08/2001 | WO2001015724A1 Improved stable formulations of ace inhibitors, and methods for preparation thereof |
| 03/08/2001 | WO2001015717A1 Brain cell or nerve cell protecting agents comprising ginseng |
| 03/08/2001 | WO2001015716A1 Plant extract mixtures and their uses |
| 03/08/2001 | WO2001015707A1 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 03/08/2001 | WO2001015706A1 Method of using dihydrochalcone derivatives to block glucose transfer |
| 03/08/2001 | WO2001015705A1 Use of fructose-1,6-diphosphate as an inotrope drug for cardiopulmonary bypass surgery |
| 03/08/2001 | WO2001015704A1 Medicaments that contain xenogenic oligo- or/and polyribonucleotides |
| 03/08/2001 | WO2001015703A1 Method for inhibiting bone resorption |
| 03/08/2001 | WO2001015702A1 Soft capsules |
| 03/08/2001 | WO2001015701A1 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| 03/08/2001 | WO2001015700A1 POLYMORPHS OF N-METHYL-N-(3-{3-[2-THIENYLCARBONYL]-PYRAZOL-[1,5-α]-PYRIMIDIN -7-YL }PHENYL )ACETAMIDE AND COMPOSITIONS AND METHODS RELATED THERETO |
| 03/08/2001 | WO2001015699A1 Injectable buprenorphine microparticle compositions and their use |
| 03/08/2001 | WO2001015698A1 Method employing imiquimod cream for treatment of topical sarcoidosis on equine |
| 03/08/2001 | WO2001015697A1 Use of at least one substance based on nicotine and/or a substance produced from said one substance for the manufacture of a medicament, and a method for treatment of obstructive lung diseases |
| 03/08/2001 | WO2001015696A1 Use of nicotine or derivatives thereof in a medicine for treating neurological diseases, in particular parkinson disease |
| 03/08/2001 | WO2001015695A1 Methods of use of fluoroquinolone compounds against bacteria |
| 03/08/2001 | WO2001015694A1 Extended duration light activated cancer therapy |
| 03/08/2001 | WO2001015693A2 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 03/08/2001 | WO2001015692A1 Methods and compositions for selective cancer chemotherapy |
| 03/08/2001 | WO2001015691A1 Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
| 03/08/2001 | WO2001015690A1 Treatment of pancreatic disease |
| 03/08/2001 | WO2001015689A1 Use of amino acids for making medicines for treating to insulin-resistance |
| 03/08/2001 | WO2001015688A1 Ibuprofen-containing softgels |
| 03/08/2001 | WO2001015687A1 Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome |
| 03/08/2001 | WO2001015686A1 Selective cox-2 inhibitory novel esters from indolealkanols and novel amides from indolealkylamines |
| 03/08/2001 | WO2001015685A1 Novel uses of sigma receptor agonists |
| 03/08/2001 | WO2001015684A2 Antimycotic drug |
| 03/08/2001 | WO2001015683A1 Delayed-action form of administration containing tramadol saccharinate |
| 03/08/2001 | WO2001015682A1 Pharmaceutical tramadol salts |
| 03/08/2001 | WO2001015681A1 Oral pharmaceutical forms of administration with a delayed action |
| 03/08/2001 | WO2001015680A1 Composition for treatment of infections of humans and animals |
| 03/08/2001 | WO2001015679A2 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders |
| 03/08/2001 | WO2001015678A2 Topical use of kappa opioid agonists to treat otic pain |
| 03/08/2001 | WO2001015677A2 Use of 5-ht1b/1d agonists to treat otic pain |
| 03/08/2001 | WO2001015676A2 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 03/08/2001 | WO2001015675A2 Use of docetaxel for treating hepatocellular carcinoma |
| 03/08/2001 | WO2001015674A2 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| 03/08/2001 | WO2001015673A2 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 03/08/2001 | WO2001015672A2 Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
| 03/08/2001 | WO2001015671A2 Flushable disposable polymeric products |
| 03/08/2001 | WO2001015670A1 Treatment of fungal infections utilizing a fungal growth medium |
| 03/08/2001 | WO2001015669A1 Pharmaceutical preparation containing nanosol |
| 03/08/2001 | WO2001015667A1 Oral dosage forms |
| 03/08/2001 | WO2001015665A1 Controlled release oral dosage suitable for oral administration |
| 03/08/2001 | WO2001015664A2 Coformulation methods and their products |
| 03/08/2001 | WO2001015654A2 Low molecular weight antithrombotic polysaccharide |
| 03/08/2001 | WO2001015593A2 Compositions for reducing vascular plaque formation and methods of using same |
| 03/08/2001 | WO2001015554A1 Metal-containing compositions, preparations and uses |
| 03/08/2001 | WO2001015553A1 Dietary food supplement containing natural cyclooxygenase inhibitors |
| 03/08/2001 | WO2001015552A1 A nutritional supplement for lowering serum triglyceride and cholesterol levels |
| 03/08/2001 | WO2001015547A2 Active agent preparation for veterinary use and method for the production thereof |
| 03/08/2001 | WO2000078751A3 Compounds for use in treatment of neurological disorders |
| 03/08/2001 | WO2000076998B1 New bispidine compounds useful in the treatment of cardiac arrhythmias |
| 03/08/2001 | WO2000073501A3 Nucleic acid molecules with specific identification of native prpsc, their production and the use thereof |
| 03/08/2001 | WO2000071754A8 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
| 03/08/2001 | WO2000071094B1 Ascorbic acid derivative composition for increasing cell renewal rate |
| 03/08/2001 | WO2000066735A3 Human ion channel proteins |
| 03/08/2001 | WO2000064416A3 Pharmaceutical formulation of tamoxifen citrate |
| 03/08/2001 | WO2000062767A3 Pharmaceutical compositions containing pyridine or pyrimidine derivates for inhibition of cytokine production and secretion |
| 03/08/2001 | WO2000059506A8 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD |
| 03/08/2001 | WO2000059448A3 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 03/08/2001 | WO2000058475A3 Streptococcus pneumoniae antigens |
| 03/08/2001 | WO2000057870A3 Viral treatment |
| 03/08/2001 | WO2000057861A3 Use of cytidine derivatives for the treatment of leukaemia |
| 03/08/2001 | WO2000054762A3 Use of cross linked polysaccharides for the inhibition of angiogenesis |
| 03/08/2001 | WO2000054760A3 Bicyclo (3.3.1) nonenes useful for the treatment of diabetes and hypertriglyceridemia |
| 03/08/2001 | WO2000050872A3 A system for cell-based screening |
| 03/08/2001 | WO2000050021A3 Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started |
| 03/08/2001 | WO2000045804A3 Use of a polyanionic polysaccharide solution for the prevention of abscess formation |
| 03/08/2001 | WO2000038786A3 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 03/08/2001 | WO2000023588A8 G-protein coupled receptors |
| 03/08/2001 | WO1999065449A8 INHIBITORS OF TRANSCRIPTION FACTOR NF-λB |
| 03/08/2001 | WO1999064047A8 Novel antiviral compounds |
| 03/08/2001 | WO1999063930A8 Novel angiotensin receptor modulators and their uses |
| 03/08/2001 | WO1999039704A8 Antibacterial agents |
| 03/08/2001 | WO1999019296A8 Aminobutanoic acid derivatives |
| 03/08/2001 | DE19942417A1 Orally administered composition for obtaining satiation effect and/or improving gastric function, containing crosslinked uronic acid-containing polysaccharide in sponge form |
| 03/08/2001 | DE19942354A1 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and use in medicaments |
| 03/08/2001 | DE19942302A1 Sulfonierte Kammpolymere mit ausgewähltem Lithium/Natrium-Verhältnis und Zubereitungen, insbesondere haarkosmetische Zubereitungen auf der Grundlage von solchen sulfonierten Kammpolymeren Sulfonated comb polymers with selected lithium / sodium ratio and preparations, in particular hair cosmetic preparations on the basis of such sulfonated comb polymers |
| 03/08/2001 | DE19941769A1 Cosmetic or dermatological active agent combination of cyclodextrin and biotin compound, useful in care or protection of skin, e.g. for treatment or prevention of aging symptoms or photodermatosis |
| 03/08/2001 | DE19941595A1 Verwendung von anellierten Benzolderivaten als Antioxidans oder Radikalfänger in kosmetischen Zubereitungen Use of fused benzene derivatives as antioxidant or free radical scavengers in cosmetic preparations |
| 03/08/2001 | DE19940415A1 Lipolytic enzyme and fatty acid binding or transport protein expression promoters comprising natural or synthetic branched fatty acids, useful as dietetic agents for reducing fat deposition and obesity |
| 03/08/2001 | DE19940227A1 Phospholipidgel Phospholipid |
| 03/08/2001 | DE19937537A1 Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate 2-substituted derivatives Dialkylaminoalkylbiphenyl |
| 03/08/2001 | CA2500709A1 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 03/08/2001 | CA2488370A1 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| 03/08/2001 | CA2419618A1 Phospholipid-coated implants |
| 03/08/2001 | CA2417639A1 Isolation of natural l-.beta.-3-indolylalanine and enrichment of natural aliphatic amino acid mixtures with natural l-.beta.-3-indolylalanine |
| 03/08/2001 | CA2403243A1 Nucleic acid based modulators of gene expression |
| 03/08/2001 | CA2391844A1 Method and formula for tumor remission and suppression of cancer |
| 03/08/2001 | CA2388560A1 Sustained-release form of administration containing tramadol saccharinate |
| 03/08/2001 | CA2388036A1 Novel uses of sigma receptor agonists |